M&A Deal Summary

Servier Acquires Agios - Oncology Business

On December 21, 2020, Servier acquired life science company Agios - Oncology Business from Agios for 2.0B USD

Acquisition Highlights
  • This is Servier’s 3rd transaction in the Life Science sector.
  • This is Servier’s largest (disclosed) transaction.
  • This is Servier’s 2nd transaction in the United States.
  • This is Servier’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-12-21
Target Agios - Oncology Business
Sector Life Science
Buyer(s) Servier
Sellers(s) Agios
Deal Type Divestiture
Deal Value 2.0B USD

Target

Agios - Oncology Business

Cambridge, Massachusetts, United States
Agios' Oncology Business is a developer of TIBSOVO® which is approved in the U.S. as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML) and for adults with newly diagnosed IDH1-mutant AML who are ≥75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Agios’ oncology pipeline and clinical programs, including vorasidenib, an investigational, brain-penetrant, dual inhibitor of mutant IDH1 and IDH2 which is currently being studied in the registration-enabling Phase 3 INDIGO study in patients with IDH-mutant low-grade glioma Agios' Oncology Business is based in Cambridge, Massachusetts.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Servier

Suresnes, France
Category Company
Founded 1954
Sector Life Science
Employees22,000
Revenue 4.2B EUR (2018)
DESCRIPTION

Servier is a pharmaceutical company governed by a non-profit foundation. Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. Servier was founded in 1954 and is based in Suresnes, France.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Divestiture) 2 of 2
State (Massachusetts) 1 of 1
Country (United States) 2 of 2
Year (2020) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-04 Symphogen AS

Ballerup, Denmark

Symphogen AS is a polyclonal antibody technology that provides a totally new, innovative class of biopharmaceuticals for treating serious human diseases. Symphogen was founded in 2000 and is based in Ballerup, Denmark.

Buy -

Seller(S) 1

SELLER

Agios

Cambridge, Massachusetts, United States
Category Company
Founded 2007
Sector Life Science
Employees383
Revenue 27M USD (2023)
DESCRIPTION

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. Agios was founded in 2007 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal